NasdaqGM:IRONBiotechs
Why Disc Medicine (IRON) Is Up 7.3% After FDA Priority Review and $250M Capital Raise
In the past week, Disc Medicine announced the initiation of a Phase 1b clinical trial for DISC-3405 in adults with sickle cell disease and reported the FDA's priority review of its New Drug Application for bitopertin in erythropoietic protoporphyria, alongside a public offering of approximately US$250 million in support of commercialization and R&D.
A key insight is that these clinical and regulatory advances highlight Disc Medicine’s emphasis on expanding its pipeline for hematological...